The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Using single-cell RNA sequencing to identify immune dysregulation in patients with MGUS and SMM
In this video, Romanos Sklavenitis-Pistofidis, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of evaluating the immune system of patients with smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) to better understand their risk of progression to active disease. Dr Sklavenitis-Pistofidis shares some findings from a study which used a large single-cell RNA-sequencing cohort of bone marrow and peripheral blood samples from patients with MGUS and SMM to identify how changes in immune cell composition and interactions in the bone marrow microenvironment play a role in disease progression. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
